<table>
<tr>
<td>Page References</td>
</tr>
<tr>
<td>
<table>
<tr>
<td>Pillar 3 Disclosure</td>
<td>Description</td>
<td>Pillar 3 Report</td>
<td>2020 Form 10-K</td>
</tr>
<tr>
<td>Introduction</td>
<td>Forward-Looking Statements</td>
<td>3</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>Basis of Consolidation</td>
<td>3</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Basel III Overview</td>
<td>3</td>
<td>2, 81, 174</td>
</tr>
<tr>
<td>Capital</td>
<td>Summary of Capital</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Restrictions on Transfer of Funds or Total Capital</td>
<td>5</td>
<td>36, 141, 143</td>
</tr>
<tr>
<td></td>
<td>Capital Adequacy</td>
<td>5</td>
<td>174</td>
</tr>
<tr>
<td></td>
<td>Capital Ratios</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Table 1: Capital Ratios</td>
<td>6</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Table 2: Standardized Risk-Weighted Assets</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Credit Risk</td>
<td>Credit Risk Management</td>
<td>7</td>
<td>61, 64</td>
</tr>
<tr>
<td></td>
<td>Summary of Credit Exposures</td>
<td>8</td>
<td>48, 49, 64, 66, 67, 68, 69, 88, 101, 119, 122, 159, 190</td>
</tr>
<tr>
<td></td>
<td>Table 3: Loan Exposures by Remaining Contractual Maturity</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Credit Risk Mitigation</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Counterparty Credit Risk</td>
<td>Counterparty Credit Risk Mitigation</td>
<td>9</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>Collateral</td>
<td>9</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>Table 4: Counterparty Credit Risk Exposures</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Securitization</td>
<td>Summary of Accounting Policies for Securitization Activities</td>
<td>10</td>
<td>133</td>
</tr>
<tr>
<td></td>
<td>Risk Management</td>
<td>10</td>
<td>101, 133</td>
</tr>
<tr>
<td></td>
<td>Table 5: Securitization Exposures by Underlying Asset Type</td>
<td>11</td>
<td>119, 122, 159</td>
</tr>
<tr>
<td></td>
<td>Regulatory Treatment of Securitizations</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Table 6: Capital Requirements of Securitization Exposures by Risk-Weighting</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Equities Not Subject to the Market Risk Rule</td>
<td>Summary of Equity Investment Exposures</td>
<td>11</td>
<td>83, 101, 147</td>
</tr>
<tr>
<td></td>
<td>Table 7: Book Value and Fair Value of Equity Exposures Not Subject to Market Risk Rule</td>
<td>12</td>
<td>83, 133</td>
</tr>
<tr>
<td></td>
<td>Table 8: Capital Requirements of Equity Investment Exposures by Risk-Weighting</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Market Risk Capital</td>
<td>Governance of Covered Positions</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valuation Policies, Procedures & Methodologies</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Value at Risk (VaR) Models</td>
<td>13</td>
<td>16, 147</td>
</tr>
<tr>
<td></td>
<td>Table 9: VaR-Based Metrics</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Back Testing</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Model Validation</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stress Testing</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Securitization Positions</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Interest Rate Risk for Non-Trading Activities</td>
<td></td>
<td>15</td>
<td>83</td>
</tr>
<tr>
<td>Supplementary Leverage Ratio</td>
<td>Table 10: Supplementary Leverage Ratio</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Glossary of Terms</td>
<td></td>
<td>16</td>
<td>196</td>
</tr>
</table>
</td>
</tr>
</table>